Chengdu Maikekang Biotechnology Co., Ltd. is identified in the article as a Chengdu‑based biotech company. The company announced a C+ round of financing on June 17, 2024. The financing amount was not disclosed in the announcement. Participating investors listed include IDG Capital, Hankang Capital, and the Qianhai Mother Fund. The article did not provide information on the company’s products, future plans, or operating metrics. The announcement was reported by DoNews and cites IT桔子 for investor information. 迈科康生物 is a high‑tech biopharmaceutical company dedicated to R&D, production and commercialization of new vaccines and novel adjuvants. The company holds a leading novel adjuvant platform, a recombinant protein expression platform, and an mRNA platform. Its pipeline includes preventive vaccines for multiple major infectious diseases and therapeutic vaccines targeting hepatitis B, allergic diseases, and cancer. These pipeline programs are described as domestic firsts with large market potential. Two independently developed innovative vaccines have entered clinical trials. The company recently completed a C‑round financing of nearly ¥300 million.

Total raised

$42M

Funding rounds

2

Latest round

Series C

Latest activity

Feb 2024